University of Virginia key CNS programs consolidate into the Brain Injury Research Program.
BIRP staff become part of the Neuroclinical Trials Center (NTC).
NTC and Integrated Neuroscience Consortium combine to form INC Research.
INC Research expands beyond CNS, adding oncology, pediatrics and data divisions.
INC Research expands into Europe with the acquisition of CRO Vujaklija – one of the first CROs in Central and Eastern Europe.
Board member Jim Ogle takes the helm as CEO.
Further expansion in Europe with the opening of an office in Germany.
QuickStart® is introduced, an innovative step ultimately leading to development of our Trusted Process®.
INC Research acquires NDDO Oncology, strengthening a key therapeutic area and further expanding in Europe. European headquarters open near London.
INC Research expands Phase IV capabilities including pharmacovigilance and drug safety through the acquisition of Pharmaceutical Resource Corporation (PRC).
INC Research expansion continues with the opening of offices in France, Russia and Ukraine.
INC Research revolutionizes the way clinical development is done, improving predictability and reliability for customers with the introduction of the Trusted Process®, our metrics-driven, clinical trials methodology.
INC Research expands its infectious disease capabilities through the acquisition of Advanced Biologics and extends its global operations into India.
INC Research expands its global footprint and therapeutic expertise through the acquisition of the therapeutic arm of MDS Pharma, adding expertise in vaccine, respiratory, cardiovascular and endocrinology therapeutic areas. The acquisition also expands INC Research into emerging markets, including Latin America, Asia/Pacific and Africa.
INC Research is recapitalized via acquisition by Avista Capital Partners and Ontario Teachers’ Pension Plan, enabling investment in further growth.
Quality Finish Camps added to Trusted Process®.
In a single year, INC Research more than doubles its size, adding therapeutic depth and strategic consulting expertise through the acquisitions of AVOS Consulting, Kendle and Trident Clinical Research.
Receives “most consistent service quality rating” in ISR CRO quality Benchmarking report, a nod to the consistency provided by the Trusted Process®.
Jamie Macdonald takes the reins as CEO.
INC Research is named “Top CRO to Work With” in the CenterWatch Global Investigative Site Relationship Survey.
750th kick-off meeting under the Trusted Process®.
INC Research continues expansion with acquisition of MEK Consulting, providing further depth in Middle East/ Northern Africa.
Approximately 6,600 employees worldwide with services provided in more than 110 countries. INC Research completes its IPO enabling innovative investments across the business to increase global reach and efficiencies.
Named SCRIP Awards “Best CRO” 2015 for our capacity to “keep up with the changing needs of our environment” and to be “an agent in driving positive change in the clinical development process.”
Ranked “Top CRO to Work With” among large global CROs in the CenterWatch Global Investigative Site Relationship Survey
Rated #1 CRO for having professional medical staff in clinical operations.
1,000th QuickStart® camp
Alistair Macdonald becomes CEO